ArriVent BioPharma, Inc.: updates and filings

AVBPNASDAQHealthcare · Pharmaceutical Preparations

Price

$11.26

November 19, 2026Market cap $582M

What Ploutos Investor adds for ArriVent BioPharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 20% since Nov 9, 2026, when the 10-Q these figures come from was filed ($14.16 then, $11.26 on Nov 19, 2026). The figures date from before that move.10-Q

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 5, 2026 latest annualNov 9, 2026 latest quarterly
  • Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 9, 2026Results of operations, officer or director change
    Form8-K
  • Nov 5, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 26, 2026Regulation FD disclosure, other material events
    Form8-K
  • Oct 19, 2026Regulation FD disclosure
    Form8-K
  • Oct 13, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Oct 13, 2026Regulation FD disclosure, other material events
    Form8-K
  • Oct 8, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Oct 6, 2026Regulation FD disclosure, other material events
    Form8-K
  • Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 12, 2026Material agreement entered, results of operations
    Form8-K
  • Jul 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jun 22, 2026Shareholder vote
    Form8-K
  • May 11, 2026Other material events
    Form8-K
  • May 11, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 11, 2026Results of operations
    Form8-K
  • May 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 28, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 28, 2026Annual meeting proxy statement
    FormDEF 14A
  • Mar 17, 2026Regulation FD disclosure, other material events
    Form8-K
  • Mar 5, 2026Shares registered for employees
    FormS-8
  • Mar 5, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 5, 2026Results of operations
    Form8-K
  • Mar 5, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 23, 2021.

The full analysis

What do ArriVent BioPharma's filings show?

The filings are where every one of ArriVent BioPharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.